Keywords: Genzyme, Sanofi, Lemtrada, Multiple sclerosis, Bayer, USA, FDA, sBLA

FDA calls on Genzyme to re-file Lemtrada sBLA

Article | 28 August 2012

Print This

French drug major Sanofi (Euronext: SAN) revealed yesterday that its US biotech subsidiary has received a Refuse to File letter ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in